|
1
|
Quoix E and Lemarié E: Epidemiological
novelties in lung cancer. Rev Mal Respir. 28:1048–1058. 2011.(In
French). View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sasaki H, Maekawa M, Tatematsu T, Okuda K,
Moriyama S, Yano M and Fujii Y: Increased BRAF copy number in lung
adenocarcinoma. Oncol Lett. 9:709–712. 2015.PubMed/NCBI
|
|
3
|
Shields PG: Molecular epidemiology of
smoking and lung cancer. Oncogene. 21:6870–6876. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Woo HI, Kim JA, Jung HA, Kim KK, Lee JY,
Sun JM, Ahn JS, Park K, Lee SY and Ahn MJ: Correlation of genetic
polymorphisms with clinical outcomes in pemetrexed-treated advanced
lung adenocarcinoma patients. Pharmacogenomics. 16:383–391. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Janardhan S, Srivani P and Sastry GN:
Choline kinase: An important target for cancer. Curr Med Chem.
13:1169–1186. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Clem BF, Clem AL, Yalcin A, Goswami U,
Arumugam S, Telang S, Trent JO and Chesney J: A novel small
molecule antagonist of choline kinase-α that simultaneously
suppresses MAPK and PI3K/AKT signaling. Oncogene. 30:3370–3380.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kwee SA, Hernandez B, Chan O and Wong L:
Choline kinase alpha and hexokinase-2 protein expression in
hepatocellular carcinoma: Association with survival. PLoS One.
7:e465912012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Granata A, Nicoletti R, Perego P, Iorio E,
Krishnamachary B, Benigni F, Ricci A, Podo F, Bhujwalla ZM,
Canevari S, et al: Global metabolic profile identifies choline
kinase alpha as a key regulator of glutathione-dependent
antioxidant cell defense in ovarian carcinoma. Oncotarget.
6:11216–11230. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shen H, Shen J, Wang L, Shi Z, Wang M,
Jiang BH and Shu Y: Low miR-145 expression level is associated with
poor pathological differentiation and poor prognosis in non-small
cell lung cancer. Biomed Pharmacother. 69:301–305. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wood SL, Pernemalm M, Crosbie PA and
Whetton AD: Molecular histology of lung cancer: From targets to
treatments. Cancer Treat Rev. 41:361–375. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Riquet M, Mordant P, Pricopi C, Legras A,
Foucault C, Dujon A, Arame A and Le Pimpec-Barthes F: A review of
250 ten-year survivors after pneumonectomy for non-small-cell lung
cancer. Eur J Cardiothorac Surg. 45:876–881. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wao H, Mhaskar R, Kumar A, Miladinovic B
and Djulbegovic B: Survival of patients with non-small cell lung
cancer without treatment: A systematic review and meta-analysis.
Syst Rev. 2:102013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vyas R, Haque S, Mital SP and Srinivasan
S: Analysis of incidence of lung cancer in various states of the
USA. International Medicine Engineering and Informatics. 7:36–45.
2015. View Article : Google Scholar
|
|
15
|
Quintans JS, Antoniolli AR, Onofre FM and
Onofre AS: Detection of lung cancer using multiple genetic markers
- a systematic review. Diagn Cytopathol. 41:834–842. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gottschling S, Jensen K, Herth FJ, Thomas
M, Schnabel PA and Herpel E: Lack of prognostic significance of
neuroendocrine differentiation and stem cell antigen co-expression
in resected early-stage non-small cell lung cancer. Anticancer Res.
33:981–990. 2013.PubMed/NCBI
|
|
17
|
Korpanty GJ, Graham DM, Vincent MD and
Leighl NB: Biomarkers that currently affect clinical practice in
lung cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front Oncol.
4:2042014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Morton CC, Aitchison AJ, Gehrig K and
Ridgway ND: A mechanism for suppression of the CDP-choline pathway
during apoptosis. J Lipid Res. 54:3373–3384. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Serran-Aguilera L, Nuti R, López-Cara LC,
Ríos-Marco P, Carrasco MP, Marco C, Entrena A, Macchiarulo A and
Hurtado-Guerrero R: Choline kinase active site provides features
for designing versatile inhibitors. Curr Top Med Chem.
14:2684–2693. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lacal JC and Campos JM: Preclinical
characterization of RSM-932A, a novel anticancer drug targeting the
human choline kinase alpha, an enzyme involved in increased lipid
metabolism of cancer cells. Mol Cancer Ther. 14:31–39. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Granata A, Nicoletti R, Tinaglia V, De
Cecco L, Pisanu ME, Ricci A, Podo F, Canevari S, Iorio E, Bagnoli M
and Mezzanzanica D: Choline kinase-alpha by regulating cell
aggressiveness and drug sensitivity is a potential druggable target
for ovarian cancer. Br J Cancer. 110:330–340. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
de la Cueva A, Ramírez de Molina A,
Alvarez-Ayerza N, Ramos MA, Cebrián A, Del Pulgar TG and Lacal JC:
Combined 5-FU and ChoKα inhibitors as a new alternative therapy of
colorectal cancer: Evidence in human tumor-derived cell lines and
mouse xenografts. PLoS One. 8:e649612013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gadiya M, Mori N, Cao MD, Mironchik Y,
Kakkad S, Gribbestad IS, Glunde K, Krishnamachary B and Bhujwalla
ZM: Phospholipase D1 and choline kinase-α are interactive targets
in breast cancer. Cancer Biol Ther. 15:593–601. 2014. View Article : Google Scholar : PubMed/NCBI
|
